Targeted therapies and radiotherapy in lung cancer;Les thérapeutiques ciblées en association avec la radiothérapie dans le cancer bronchique

Cancer/Radiotherapie

Volumn 11, Issue 1-2, 2007, Pages 77-83

  Hennequin, C ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Lung cancer; Radiotherapy; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DEATH; HEMOPTYSIS; HUMAN; LUNG CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; SHORT SURVEY; SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34047135709     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2006.09.036     Document Type: Short Survey

References (72)

1. Akimoto T., Hunter N., Buchmiller L., Mason K., Kian Ang K., and Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 5 (1999) 2884-2890
2. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radioth. Oncol. 72 (2004) 257-266
3. Bianco C., Tortora G., Veneziani B., Caputo R., Damiano V., Troiani T., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor. Clin. Cancer Res. 8 (2002) 3250-3258
4. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
5. Bunn Jr. P.A., and Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin. Oncol. 29 (2002) 38-44
6. Camphausen K., Moses M., Beecken W., Khan M., Folkman J., and O'Reilly M. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 61 (2001) 2207-2211
7. Carmeliet P., and Jain R. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
8. Carter C.A., Chen C., Brink C., Vincent P., Maxuitenko Y.Y., Gilbert K.S., et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol (2006)
9. Ciardiello F., Bianco R., Caputo R., Damiano V., Troiani T., Melisi D., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 10 (2004) 784-793
10. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7 (2001) 1459-1465
11. Ciardiello F., Caputo R., Damiano V., Troiani T., Vitagliano D., Carlomagno F., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9 (2003) 1546-1556
12. Eriksen J., Steiniche T., Askaa J., and Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 561-566
13. Ettinger D.S. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist 11 (2006) 358-373
14. Fowler J., and Lindstrom M. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23 (1992) 457-467
15. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21 (2003) 2237-2246
16. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 300
17. Gatzemeier U., Pluzanska A., and Szczesna A. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 23 (2004) 617a
18. Geng L., Donnelly E., McMahon G., Lin P., Sierra-Rivera E., Oshinka H., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61 (2001) 2413-2419
19. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J. Clin. Oncol. 22 (2004) 777-784
20. Giocanti N., Hennequin C., Rouillard D., DeFrance R., and Favaudon V. Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro. Br. J. Cancer 13 (2004) 2026-2033
21. Gorski D.H., Beckett M., Jaskowiak N., Calvin D., Mauceri H., Salloum R., et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59 (1999) 3374-3378
22. Hansen-Algenstaedt N., Stoll B., Padera T., Dolmans D., Hicklin D., Fukumura D., et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelialgrowth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60 (2000) 4556-4560
23. Hartford A., Gohongi T., Fukumura D., and Jain R. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppressiojn at a distal site: potential role of host-tumor interaction. Cancer Res. 60 (2000) 2128-2131
24. Hennequin C., Giocanti N., and Favaudon V. Thérapeutiques ciblées et radiothérapie. Bull. Cancer 92 (2005) 1085-1092
25. Herbst R.S., and Bunn Jr. P.A. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res. 9 (2003) 5813-5824
26. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J. Clin. Oncol. 22 (2004) 785-794
27. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 2544-2555
28. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 5892-5899
29. ®"). Cancer Res. 2002 (2002) 4300-4306
30. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
31. ®) trials in non-small cell lung cancer. Lung Cancer 41 (2003) S23-S28
32. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22 (2004) 2184-2191
33. Kelly K., Gaspar L., and Chansky K. Low incidence of pneumonitis on SWOG 0023. A preliminary analysis of an on-going phase III trial of concurrent chemoradiotheraoy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III NSCLC. Proc. Am. Soc. Clin. Oncol. 23 (2005) (Abs. 7058)
34. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
35. Kozin S., Boucher Y., Hicklin D., Bohlen P., Jain R., and Suit H. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61 (2001) 39-44
36. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
37. Lee C., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response inder normoxic and hypoxic conditions. Cancer Res. 60 (2000) 5565-5570
38. Lordick F., Geinitz H., Theisen J., Sendler A., and Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 1295-1298
39. Lynch T., Bell D., Sordella R., Gurubhagavatula S., Okimoto R., Brannigan B., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
40. ®') in combination with cytotoxic treatment in human head and neck cancer. Br. J. Cancer 86 (2002) 818-827
41. Mauceri H.J., Hanna N.N., Beckett M.A., Gorski D.H., Staba M.-J., Stellato K.A., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394 (1998) 287-291
42. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur. Respir. J. 20 (2002) 975-981
43. Meert A.P., Paesmans M., Martin B., Delmotte P., Berghmans T., Verdebout J.M., et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer 87 (2002) 694-701
44. Moeller B., Cao Y., Vujaskovic Z., Li C., Haroon Z., and Dewhirst M. The relationship between hypoxia and angiogenesis. Semin. Radiat. Oncol. 14 (2004) 215-221
45. Natale R.B., Bodkin D., Govindan R., Sleckman B., Rizvi N., Capo A., et al. ZD6474 vs gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. Proc. Am. Soc. Clin. Oncol. 24 (2006) 364s
46. O'Reilly M. The combination of antiangiogenic therapy with other modalities. Cancer J. 8 (2002) S89-S99
47. Petersen C., Eicheler W., Frommel A., Krause M., Balschukat S., Zips D., et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int. J. Radiat. Biol. 79 (2003) 469-477
48. Pore N., Jiang Z., Gupta A., Cerniglia G., Kao G.D., and Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 66 (2006) 3197-3204
49. Sandler A.B., Gray R., Brahmer J., Dowlati A., Schiller J.H., Perry M.C., et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc. Am. Soc. Clin. Oncol. 23 (2005) (Abs. 4)
50. Sandler A.B., Johnson D.H., Brahmer J., Schiller J.H., Ostland M., Gray R., et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary haemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 24 (2006) 381s
51. Scappaticci F. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20 (2002) 3906-3927
52. Schmidt-Ullrich R., Contessa J., Dent P., Mikkelsen R., Valerie K., Reardon D., et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat. Oncol. Investig. 7 (1999) 321-330
53. Schmidt-Ullrich R., Mikkelsen R., Dent P., Todd D., Valerie K., Kavanagh B., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
54. Schmidt-Ullrich R., Valerie K., Fogleman P., and Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in malignant mammary and squamous epithelial cells. Radiat. Res. 145 (1996) 81-85
55. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353 (2005) 123-132
56. Shintani S., Li C., Mihara M., Terakado N., Yano J., Nakashiro K., et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int. J. Cancer 107 (2003) 1030-1037
57. ®") potentiates the antitumor effects of single and multiple frcations of ionizing radiation in human A431 squamous cell carcinoma. Int. J. Radiat. 0ncol. Biol. Phys. 55 (2003) 713-723
58. Teicher B., Emi Y., and Kakeji Y. TNP-470/minocyclin/cytotoxic therapy: a systems approach to cancer therapy. Eur. J. Cancer 32 (1996) 2461-2466
59. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
60. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11 (2005) 1167-1173
61. Tortora G., Caputo R., Damiano V., Troiani T., Veneziani B.M., De Placido S., et al. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin. Cancer Res. 9 (2003) 866-871
62. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353 (2005) 133-144
63. Tuccillo C., Romano M., Troiani T., Martinelli E., Morgillo F., De Vita F., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin. Cancer Res. 11 (2005) 1268-1276
64. Wachsberger P., Burd R., and Dicker A. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring the mechanisms of interaction. Clin. Cancer Res. 9 (2003) 1957-1971
65. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
66. Willett C., Boucher Y., di Tomaso E., Duda D., Munn L., Tong R., et al. Direct evidence taht the VEGF-antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 (2004) 145-147
67. Williams K., Telfer B., Stratford I., and Wedge S.Z.D. 1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer 86 (2002) 1157-1161
68. Williams K.J., Telfer B.A., Brave S., Kendrew J., Whittaker L., Stratford I.J., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. 10 (2004) 8587-8593
69. Winkler F., Kozin S., Tong R., Chae S., Booth M., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
70. Withers H.R., Taylor J.M., and Maciejesky B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27 (1988) 131-146
71. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. 19 (2001) 432-441
72. Zips D., Hessel F., Krause M., Schieffer Y., Hoinkis C., Thames H., et al. Impact of adjuvant inhibition of vascular endothelial growth factor recpetor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int. J. Radiat. 0ncol. Biol. Phys. 61 (2005) 908-914